INDP has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
INDP has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Indaptus Therapeutics's Cash per Share for the quarter that ended in Mar. 2024 was $1.14.
The historical data trend for Indaptus Therapeutics's Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Indaptus Therapeutics Annual Data | |||||||||
Trend | Dec20 | Dec21 | Dec22 | Dec23 | |||||
Cash per Share | 0.30 | 4.74 | 3.15 | 1.59 |
Indaptus Therapeutics Quarterly Data | ||||||||||||||||
Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Cash per Share | Get a 7-Day Free Trial | 2.58 | 2.34 | 1.90 | 1.59 | 1.14 |
This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.
Indaptus Therapeutics's Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as:
Cash per Share | = | Cash, Cash Equivalents, Marketable Securities | / | Shares Outstanding (EOP) |
= | 13.362 | / | 8.40 | |
= | 1.59 |
Indaptus Therapeutics's Cash per Share for the quarter that ended in Mar. 2024 is calculated as:
Cash per Share | = | Cash, Cash Equivalents, Marketable Securities | / | Shares Outstanding (EOP) |
= | 9.742 | / | 8.54 | |
= | 1.14 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Indaptus Therapeutics (NAS:INDP) Cash per Share Explanation
Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.
Thank you for viewing the detailed overview of Indaptus Therapeutics's Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Glen R. Anderson | 10 percent owner | 3274 ROSS ROAD, PALO ALTO CA 94303 |
Roger J. Waltzman | officer: Chief Medical Officer | C/O JAGUAR ANIMAL HEALTH, INC., 201 MISSION STREET, SUITE 2375, SAN FRANCISCO CA 94105 |
Robert Martell | director | 4 MAGUIRE ROAD, LEXINGTON MA 02421 |
Boyan Vesselinov Litchev | officer: Chief Medical Officer | 13357 RUSSET LEAF LN., SAN DIEGO CA 92129 |
Jeffrey A Meckler | director, officer: Chief Executive Officer | 740 BROADWAY, 9TH FLOOR, NEW YORK NY 10003 |
Walt Addison Linscott | officer: Chief Business Officer | 1860 MONTREAL ROAD, TUCKER GA 30084 |
Michael James Newman | director, 10 percent owner, officer: Chief Scientific Officer | C/O INTEC PARENT, INC., 12 HARTOM ST., HAR HOTZVIM, JERUSALEM L3 9777512 |
Mark John Gilbert | director | 13731 NORTHWOOD RD., NW, SEATTLE WA 98177 |
Brian O'callaghan | director | 550 HILLS DRIVE, 3RD FLOOR, BEDMINSTER NJ 07921 |
Hoonmo Lee | director, 10 percent owner | C/O INTEC PARENT, INC., 12 HARTOM ST., HAR HOTZVIM, JERUSALEM L3 9777512 |
Anthony J Maddaluna | director | PFIZER INC. ATTN CORPORATE SECRETARY, 235 RAST 42ND STREET, NEW YORK NY 10017 |
William B Hayes | director | 231 MAPLE AVENUE, BURLINGTON NC 27215 |
Roger Pomerantz | director | 711 HARVEST HILL ROAD, CHALFONT PA 18914 |
Hila Karah | director | 9 HALAMISH STREET, CAESAREA INDUSTRIAL PARK, CAESAREA L3 38900 |
Nir Sassi | officer: Chief Financial Officer | 3 ELUL STREET, APT. 6, MODIIN L3 7176397 |
From GuruFocus
By sperokesalga sperokesalga • 04-20-2023
By Marketwired • 09-06-2023
By Marketwired • 09-19-2023
By GuruFocusNews GuruFocusNews • 06-23-2022
By sperokesalga sperokesalga • 05-31-2023
By sperokesalga sperokesalga • 04-19-2023
By sperokesalga sperokesalga • 04-19-2023
By sperokesalga sperokesalga • 02-14-2023
By GuruFocusNews GuruFocusNews • 07-07-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.